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SUMMARY. Cystic adenomatoid lung malformation (CCAM) is a rare disease, with a prevalence 1/25 000 to 1/35 000
pregnancies, a developmental abnormality arising from an overgrowth of the terminal respiratory bronchioles. Prenatal
diagnosis is based on the ultrasonographic demonstration of a hyperechogenic pulmonary tumor, which is microcystic or
macrocystic. The disease may be associated with a mediastinal shift, hydrops fetalis or polyhydramnios. The outcome is
bad in bilateral cases, in those with pulmonary hypoplasia and with fetal hydrops. In unilateral and isolated cases the prog-
nosis may be good. Spontaneous resolution occurs prenatally only in the third trimester of pregnancy. Three cases of
CCAM are presented. The case of type I was diagnosed at 28 weeks and regression occured in the third trimester, at 36
weeks of gestation. The prenatal and postnatal pictures of a case of the lung type II and of a case of CCAM type III with
echogenic appearance of a uniformly solid mass, are presented too.
Pregled
Klju~ne rije~i: priro|ena cisti~na adenomatoidna malformacija plu}a, prenatalna dijagnostika, ultrazvuk, fetalna
terapija
SA@ETAK. Cisti~na adenomatoidna malformacija plu}a (CACM) je rijetka bolest s pojavno{}u od 1/25 000 do 1/35 000
trudno}a, razvojna pogrje{ka koja nastaje prera{tanjem terminalnih respiratornih mjehuri}a. Prenatalna dijagnoza se
zasniva na ultrazvu~nom prikazu hiperehogenog tumora plu}a, koji mo`e biti mikrocisti~an i makrocisti~an. Pri bolesti
mo`e nastati pomak medijastinuma, fetalni hidrops ili polihidramnios. Ishod je lo{ u bilateralnim slu~ajevima, u onima s
hipolazijom plu}a i fetalnim hidropsom. U jednostranim i izoliranim slu~ajevima prognoza mo`e biti dobra. Spontani
nestanak se zbiva u tre}em tromjese~ju trudno}e. Prikazana su tri ploda s CCAM. Tip 1 bolesti je bio dijagnosticiran u
fetusa s 28 tjedana i regresija je nastupila s 36 tjedana. Prikazane su prenatalne i postnatalne slike slu~aja s ultrazvu~nim
nalazom jednakomjerno solidne mase s tipom II i s tipom III bolesti.
Introduction
Congenital cystic adenomatoid malformation (CCAM)
of the lung is a developmental abnormality arising from
an overgrowth of the terminal respiratory bronchioles.
Prenatal diagnosis is based on the ultrasonographic de-
monstration of a hyperechogenic pulmonary tumor, which
is microcystic or macrocystic. Both microcystic and
macrocystic disease may be associated with mediastinal
shift, hydrops fetalis or polyhydramnios. Prognostic
features for poor outcome include bilateral disease, or
unilateral with major lung compression causing pulmo-
nary hypoplasia, and development of hydrops fetalis ir-
respective of the type of the lesion. Isolated unilateral
cystic adenomatoid malformation without hydrops is as-
sociated with a good prognosis. Prenatal treatment is al-
most exclusivelly surgical. Procedures are lobar resec-
tion or thoraco-amniotic shunt. Symptom-free cysts
undergo conservative treatment and serial ultrasonogra-
phic follow-up. Spontaneous resolution occurs prena-
tally only in the 3-rd trimester of pregnancy. Postnatal
management is more comfortable: segmental or lobar
resection.
The congenital cystic adenomatoid abnormality is a
hamartomatous lesion arising from abnormal embryo-
genesis during the first trimester of pregnancy. Exces-
sive growth of adenomatoid tissue in terminal bronchi-
oles area consequently supresses bronchiolar and
alveolar development
1
; the result is a lack of normal al-
veolar structure of the pulmonary air space. The distal
displastic lung tissue is secondary to bronchiolar atresia,
regarded as the primary abnormality.
2
In 98% of cases the lesions are unilateral and confined
in 95% of cases to a single lobe (Figures 1, 2, 3). The
middle lobe is the most protected. Extrapulmonary le-
sions are quite rare; a single intraabdominal, suprarenal
case was mentioned in the literature.
2
The prevalence of the disease is still uncertain: it is
considered to be somewhere between 1/25 000 and
1/35 000 pregnancies, but most of the symptom-free,
microcystic cases were probably subdiagnosed until re-
cently.
3
CCAM is the most frequent lung abnormality. At
least 25% of cases, considerably more if we consider
also the subclinical cases diagnosed using recent tech-
niques.
3
The risk for recurrence in subsequent pregnan-
cies is practically absent (sporadic disease). The de-
pendence on race, maternal age or genetic/family his-
tory is still undocumented, as well as the vague predilec-
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tion for male sex. In about 10% of cases, CCAM is
associated with other abnormalities and fetal malforma-
tions: trisomy 18, renal agenesis, congenital diaphrag-
matic hernia, heart defect.
3
Diagnosis
In 1979, Stocker classified CCAM according to cystic
size and distribution, also trying to establish a prognos-
tic relationship. This is now infirmed (see prognostic
groups and criteria in CCAM):
• CCAM type I (50% of cases): single/multiple cysts,
with large diameters (2–10 cms), air-filled or fluid-
filled and with variable wall thickness; excellent
prognosis (Fig. 4, 5).
• CCAM type II (40% of cases): multiple, medium-
diameter (0.5–2 cm), thin walled cysts (Fig. 1, 2);
poor prognosis only if associated with other con-
genital abnormalities. Otherwise the mediastinal
shift is small and the respiratory distress is mild.
4
• CCAM type III (10% of cases): multiple microcysts
(smaller than 0.5 cm), with echographic appearance
of a uniformly solid mass, mostly located in the left
lower lobe; bad prognosis due to constant associa-
tion with pulmonary hypoplasia and hydrops fe-
talis.
5–7
Recent trends are towards a simplified ultrasonogra-
phic classification as microcystic (40%) and macro-
cystic disease (60%). Both forms can be associated with
mediastinal shift, compression and hydrops fetalis, but
even with the most up-to-date imaging techniques, very
small microcystic lesions are still difficult to detect.
A specific CCAM feature is reduced local vascu-
larization associated with increased cell proliferation.
Cystic vascularization derives from pulmonary circula-
tion and communicates with the bronchial tree (differen-
Figure 1. CCAM, a case diagnosed at 24 weeks, showing numerous cystic
lesions in the lower right pulmonary lobe. Axial view
Slika 1. Slu~aj dijagnosticiran s 24 tjedana, prikazane su brojne cisti~ne
tvorbe u desnom donjem plu}nom re`nju. Aksijalni ultrazvu~ni presjek
Figure 2. CCAM, a case diagnosed at 24 weeks, showing numerous cystic
lesions in the lower right pulmonary lobe. Transverse 4 chamber view. A
minor degree of mediastinal shift is associated
Slika 2. Slu~aj dijagnosticiran s 24 tjedna, prikazane su brojne cisti~ne
tvorbe u desnom donjem plu}nom re`nju. Popre~ni ultrazvu~ni presjek
kroz 4 sr~ane komore. Pomak medijastinuma manjeg stupnja
Figure 3. Postabortum aspect of CCAM of the lower right pulmonary lobe
in a 24 weeks fetus. Up: The right pulmonary lobe is occupying a large
part of thorax. Down: Macroscopic aspect of the disected lung
Slika 3. Desni donji plu}ni re`anj u fetusa od 24 tjedna nakon poba~aja.
Gore: desni plu}ni re`anj zauzima veliki dio prsi{ta. Dolje: makroskopski
izgled diseciranih plu}a
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tial diagnosis with pulmonary sequestration). Cystic walls
contain mucous metaplasic cells, stem mesenchymal
cells and differentiated rough muscle fibers, poorly or-
ganized, as well as ectopic neural tissue, as shown by the
presence of neuron-specific enolase and glial fibrilar
acid protein (typical for astrocytes). The glandular part
is also important: nodular agregates of mucoid cells, al-
most identical to mucous cells in bronchiolo-alveolar
carcinoma and hyperplastic polyps of the colon. These
are enough observations to support the hypothesis of
disregulated paracrine growth of mature cells and
extracellular matrix as a cause for CCAM. The glandu-
lar part of the lesions has a potential for malignant evo-
lution.
5
Prenatal diagnosis is incidental in most of the cases by
routine ultrasound.
8
Sonographically, CCAM appears as
solid or mixed cystic and solid (microcystic) noncom-
pressible chest masses in the fetus. CCAM can be very
large and contains large cysts (Fig.4), and just like any
chest mass, they have potential to compress the develop-
ing lungs and cause pulmonary hypoplasia and hydrops.
Sonographic diagnosis of a CCAM is often made at 16
to 22 weeks, and early diagnosis is favored by large size
and presence of macrocysts.
9
A positive diagnosis
makes the premises for weekly serial ultrasounds, once
a week, then once every 2 to 4 weeks, as an assessment
tool for the cystic evolution.
MRI remains the method of election for differential
diagnosis with other congenital lung anomalies (con-
genital lobar emphysema, pulmonary sequestration,
bronchogenic cyst). MRI allows early diagnosis of le-
thal complications – severe mediastinal shift, with com-
pression of lung tissue. The same techniques remain
useful for the postnatal diagnosis, too. On ultrasound,
lung masses are glandular or bronchiolar structures,
sometimes associated with endogenous lipoid areas.
Hypodensities are microcysts associated with normal
lung tissue. The computed tomography demonstrates
non-infected lesions as air-filled, thin-walled masses;
infected lesions show a more complex appearance, due
to the presence of fluid and inflammatory tissue.
10
The differential diagnosis excludes all lung and me-
diastinal tumors and cavities: congenital diaphragmatic
hernia (CDH), pulmonary sequestration, staphylococcal
pneumatoceles, cavitary pneumonia, congenital lobar
emphysema, airway atresia, bronchogenic cyst, peri-
cardial cyst, mediastinal teratoma, etc.
The various clinical features are produced by lung
compression and mediastinal shift. Compression on
heart and inferior vena cava decreases venous return and
cardiac output and leads to fetal hydrops, sometimes
mirrored by maternal preeclampsia. Esophageal com-
pression is responsible for polyhydramnios. Intrauterine
Figure 4. CCAM, a case diagnosed at 28 weeks showing a cyst of 26 mm.
Transverse view
Slika 4. Ultrazvu~na slika CCAM u fetusa od 28 tjedana. Vidi se cista od
26 mm. Popre~ni presjek
Figure 5. CCAM, transverse view of the lower part of thorax at 28 weeks
fetus
Slika 5. CCAM, popre~ni ultrazvu~ni presjek donjeg dijela prsi{ta u fetusa
od 28 tjedana
Figure 6. Regression of the lesion in the lower left pulmonary lobe at 36
weeks of gestation
Slika 6. Regresija lezije donjeg lijevog plu}nog re`nja s 36 tjedana
trudno}e
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growth restriction could induce fetal demise or prema-
ture birth (large cysts, no surgical resection). Some
cases undergo spontaneous in utero resolution (differen-
tial diagnosis with CDH). Other are symptom-free post-
natal (in stable, non-growing cystic lesions).
11,12
Partial
regression of the lung cystic mass is encountered in
about 50–70% of cases (recent studies based on serial
ultrasounds) (Fig.6).
3,13
Although the classic opinion on early postnatal period
emphasized the high percentage of cases with respira-
tory distress, induced by hydrops, premature delivery,
pulmonary hypoplasia, spontaneous pneumothorax, re-
cent studies demonstrate excellent neonatal prognosis
for stable lesions, with surgical or even conservative
treatment.
14–16
Later on, recurrent lung infections are
common and important prognostic indicator.
Some cases evolve through malignancy: 25% of pleu-
ro-pulmonary blastoma is found in children with CCAM.
Recent information focus on the following prognostic
factors: cystic size (irrespective of echostructure), bila-
terality, degree of mediastinal shift, presence or absence
of polyhydramnios and hydrops, association with other
malformations. Based on these factors, fetal CCAM is
classified in several prognostic groups: good, undeter-
mined and poor. For example, a fetus with a small, sta-
ble CCAM with little mediastinal shift has an excellent
prognosis. This optimism is attributable to three impor-
tant observations in fetuses with CCAM. First, it is ex-
tremely rare for a small unilateral CCAM, with only
mild cardiomediastinal shift, to cause hydrops. Second,
it is very rare for a lesion that is small when first iden-
tified to progress sufficiently in gestation to cause hy-
drops or significant pumonary hypoplasia. Third, in the
absence of concomitant abnormalities, empiric survival




reported that, in a period of 10 years,
among 28 cases of CCAM, five pregnancies were termi-
nated, 23 pregnancies continued and resulted in 2 neo-
natal deaths and 21 surviving babies. Lerullo et all.
16
re-
ported an overall survival rate of 88%. As more fetuses
with CCAM are studied, it has become clear that the ma-
jority of masses detected remain stable or regress in size
(close to 100% if no associated malformations). Unfor-
tunately, regression may not occur until the third trimes-
ter, and those lesions that will regress are not yet predict-
able on the basis of midgestation sonogram.
17,18
So, it is
recommended that all fetuses be monitored carefully.
The presence of hydrops (100% mortality) and sever-
ity of mediastinal shift are coreleted with the size of the
lesion.
19
Very large lesions cause more mediastinal shift
and are more likely to cause hydrops. Four CCAM cases
with in-utero resolution of hydrops fetalis after prenatal
betamethasone therapy with good clinical outcome have
been reported in literature. The mechanism is speculated
to be the effect of corticosteroid in improving lung mat-
uration.
20,21
The initial rapport between dimensions of CCAM and
thorax does not impact upon the vital and functional
prognosis.
6,7
Early antenatal diagnosis, made possible
by modern imaging techniques, allows early interven-
tions on children population asymptomatic at birth.
22
Fetal therapy
Prenatal treatment is almost exclusively surgical and
may be delayed until partial delivery, when the fetus still
has placental circulatory support (EXIT = ex utero intra-
partum treatment).
23
Candidates for fetal surgery are less than 32 weeks
gestational age, hydrops fetalis,
18
placentomegaly and/or
an onset of maternal preeclampsia. Fetuses older than 32
weeks allow delivery by cesarean section and postnatal
surgery. There is no surgical intervention less than 28
weeks, unless fetal heart failure, but not associated with
preeclampsia.
Except for lobar resection, a thoraco-amniotic shunt
for mediastinal compression relief is also a possibility.
This procedure is quite rare, due to a high rate of compli-
cations and it was indicated only to those cases compli-
cated by major polyhydramnios or hydrops.
13,24
Symp-
tom-free cysts undergo conservative treatment and se-
rial ultrasonographic follow-up. Maternal digitalisation
is sometimes efficient in hydrops correction. Serial
amniocentesis can be performed for polyhydramnios.
Irrespective of which fetal procedure was applied, we
must emphasize that no method is a cure for maternal
pre/eclampsia.
12,25–27
Postnatal management is more comfortable: segmen-
tal or lobar resection may be performed through endo-
scopic techniques or thoracotomy, depending on clinical
forms. More recent techniques focus on non-anatomic
resection, fragments of lung tissue having a surprisingly
high ability of expansion and functional recovery until
the age of 9. Most authors preffer surgical cure for
asymptomatic cases, due to the risk for malignancy. If
no complications arise, optimal age for surgical inter-
vention is somewhere between 3 and 6 months. A rather
rare technique, with uncertain results, is vascular embo-
lisation of the cyst.
25,26
As a rule, symptomatic newborns undergo surgical
procedures after a firm computer tomography (CT) di-
agnosis was obtained
23
, while symptom-free babies, ir-
respective of radiological aspects, are discharged with a
follow-up CT scan at the age of 3 months.
25
Interven-
tions performed after the first month of life demonstrate
a better outcome compared to early neonatal surgery.
28
Postoperative complications in fetal surgery are im-
portant: premature delivery or premature rupture of
membranes. Postnatal outcome includes pneumothorax,
pleural effusions, portal vein thrombosis or pulmonary
hemorrhage, requiring a second intervention. It has al-







lution occurs only prenatal, in the 3-rd trimester of preg-
nancy.
17
Constant improvement in accuracy for the pre-
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natally diagnosis allows both a strict selection of cases
for in utero interventions and optimal timing for
postnatal surgery; thus, postoperative complications and
the period of hospitalization are decreased.
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